A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: transport (210), delivery (625)

Audit and Risk Committee ToR Jan 2023

Description
Audit and Risk Committee Terms of Reference Version: 5 Date Issued: Review Date: Document Type: 31 January 202
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2023.pdf

Audit and Risk Committee ToR Jan 2022

Description
Audit and Risk Committee Terms of Reference Date Issued: 27 January 2022 Review Date: January 2023 Document Ty
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2022.pdf

Von Hippel-Lindau disease (VHL) - patient information

Description
Information about von Hippel-Lindau (VHL) disease.
Url
/Media/UHS-website-2019/Patientinformation/Genetics/Von-Hippel-Lindau-disease-VHL-1438-PIL.pdf

Information for patients who have tested positive for CPE - patient information

Description
Information for patients who have tested positive for CPE.
Url
/Media/UHS-website-2019/Patientinformation/Tests/Information-for-patients-who-have-tested-positive-for-CPE-1232-PIL.pdf

Food allergy in schools and nurseries - patient information

Description
Most schools and nurseries have systems in place to help children with food allergies. Here are some tips to make sure
Url
/Media/UHS-website-2019/Patientinformation/Childhealth/Food-allergy-in-schools-and-nurseries-2430-PIL.pdf

RFC_PO

Description
Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA RFC-CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (PO) Regimen • CLL – RFC (PO)-Cyclophosphamide-Fludarabine-Rituximab (PO) Indication • Chronic Lymphocytic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-PO.pdf

RFC_PO_Split

Description
Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (PO-Split) Regimen • CLL – RFC (PO)-Cyclophosphamide-Fludarabine-Rituximab (PO-Split) Indication • Chronic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-PO-Split.pdf

RFC_IV

Description
Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (IV) Regimen • CLL – RFC (IV)-Cyclophosphamide-Fludarabine-Rituximab (IV) Indication • Chronic Lymphocytic Leukaemia
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-IV.pdf

RFC_IV_Split

Description
Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (IV-Split) Regimen • CLL – RFC (IV)-Cyclophosphamide-Fludarabine-Rituximab (IV-Split) Indication • Chronic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-IV-Split.pdf

COV001_PIS_v5.0_21_Apr_2020_localised

Description
Southampton NIHR Clinical Research Facility University Hospital Southampton NHS Foundation Trust C Level West Wing, Mailpoint 218 Southampton SO16 6YD Te
Url
/Media/Southampton-Clinical-Research/COVID-19/Vaccine-trial/COV001-PIS-v5.0-21-Apr-2020-localised.docx
151 to 160 of 573
Previous … 14 15 16 17 18 … Next